Rights and Permissions
Evanthia Galanis, S Keith Anderson, Erin Twohy, Nicholas A Butowski, Adilia Hormigo, David Schiff, Antonio Omuro, Kurt A Jaeckle, Shaji Kumar, Timothy J Kaufmann, Susan Geyer, Priya U Kumthekar, Jian Campian, Caterina Giannini, Jan C Buckner, Patrick Y Wen, Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance), Neuro-Oncology Advances, Volume 4, Issue 1, January-December 2022, vdac041, https://doi.org/10.1093/noajnl/vdac041.
© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact email@example.com.
Galanis, Evanthia; Campian, Jian; and et al., "Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)." Neuro-Oncology Advances. 4, 1. vdac041 (2022).